Page last updated: 2024-11-12

glycoursodeoxycholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycoursodeoxycholic acid : A bile acid glycine conjugate derived from ursoodeoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

glycoursodeoxycholate : A N-acylglycinate that is the conjugate base of glycoursodeoxycholic acid. obtained by deprotonation of the carboxy group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID12310288
CHEMBL ID409348
CHEBI ID89929
SCHEMBL ID231609
MeSH IDM0081926

Synonyms (46)

Synonym
glycoursodeoxycholate
64480-66-6
gudca
glycine ursodeoxycholic acid
glycoursodeoxycholic acid
CHEMBL409348 ,
chebi:89929 ,
ccris 9498
pf1g5j2x2a ,
unii-pf1g5j2x2a
ursodeoxycholylglycine
glycine, n-((3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl)-
bdbm50375586
3.alpha.,7.beta.-dihydroxy-5.beta.-cholanoylglycine
glycylursodeoxycholic acid
n-(3.alpha.,7.beta.-dihydroxy-5.beta.-cholan-24-oyl)glycine
S6146
glycine, n-[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]-
gtpl4715
2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
SCHEMBL231609
ursodeoxycholylglycine, (+)-
n-((3.alpha.,5.beta.,7.beta.)-3,7-dihydroxy-24-oxocholan-24-yl)glycine
glycine, n-((3.alpha.,5.beta.,7.beta.)-3,7-dihydroxy-24-oxocholan-24-yl)-
3alpha,7beta-dihydroxy-5beta-cholanoyl glycine
n-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)glycine
n-[(3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl]glycine
mfcd00137427
3alpha,7beta-dihydroxy-5beta-cholanoylglycine
n-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)-glycine
LMST05030016
AKOS027250703
glycoursodeoxycholic acid, >=96.0% (tlc)
AS-58487
st 24:1;o3;g
3a,7b-dihydroxy-5b-cholanoylglycine
n-[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]glycine
glycylursodeoxycholate
n-(3a,7b-dihydroxy-5b-cholan-24-oyl)glycine
HY-N1424
CS-6300
Q27077819
AMY40653
D78413
A867877
DTXSID20862344

Research Excerpts

Actions

ExcerptReferenceRelevance
"Glycoursodeoxycholic acid failed to cause any of the effects observed for GCDCA or paracetamol."( Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells.
Gonzalez-Buitrago, JM; Gonzalez-Loyola, A; Gonzalez-Sanchez, E; Marin, JJ; Perez, MJ, 2011
)
1.09

Toxicity

ExcerptReferenceRelevance
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
bile acid glycine conjugateAmide of a bile acid with glycine.
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile acid receptorHomo sapiens (human)IC50 (µMol)98.40000.01834.560310.0000AID1847960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)33.90000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km5.30004.30006.39608.8000AID681360
Ileal sodium/bile acid cotransporterHomo sapiens (human)Km4.10002.00005.30009.4000AID678823
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (57)

Processvia Protein(s)Taxonomy
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1848070Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction of bile acid pool size in ileum2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848057Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction of dihydroceramide level in serum administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1847961Cytotoxicity against HEK293T cells cotransfected with pCMV-Script-hFXR/pGL4.11-hSHP-Luciferase incubated for 24 hrs in presence of GW4064 by celltiter-blue cell viability assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1847979Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced Fgf15 mRNA expression in ileum at 10 mg/kg, po incubated for 2 to 48 hrs2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848073Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as bile acid level in gall bladder2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848011Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as upregulation of Pgcl-alpha expression in inguinal white adipose tissue at 50 mg/kg2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848063Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as cholesteryl level administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID1848069Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as increase in hepatic bile acid synthesis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848009Anti-NASH activity in GAN-induced mouse C57/BL67 assessed as increase in rectal temperature at 50 mg/kg2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1847960Antagonist activity at FXR (unknown origin) expressed in HEK293T cells cotransfected with pCMV-Script-hFXR/pGL4.11-hSHP-Luciferase incubated for 24 hrs in presence of GW4064 by Steady-glo luciferase assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848002Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in fat mass at 50 mg/kg, IG measured after 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848061Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as free fatty acid level administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848007Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as increase in glucose tolerance at 50 mg/kg2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1847980Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced FXR mRNA expression in hepatic signaling at 10 mg/kg, po incubated for 2 to 48 hrs2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID1848059Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction of sphinogo-myelin level in serum administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848058Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction of glycosyl-ceramide level in serum administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848001Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in lean mass at 50 mg/kg IG measured after 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848006Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in fasting glucose level at 50 mg/kg measured upto 120 mins2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848008Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as increase in insulin sensitivity at 50 mg/kg2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID680222TP_TRANSPORTER: uptake of Glycoursodeoxycholate at 20 u M in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID1848004Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in random blood glucose level at 50 mg/kg measured upto 120 mins2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848060Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction of ceramide level in serum administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848018Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as decrease in hydroxyproline in liver2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848062Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as triacylglycerol level administered orally for 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID681352TP_TRANSPORTER: transepithelial transport (basal to apical) in Ntcp/Bsep double transfected MDCK cell2005American journal of physiology. Gastrointestinal and liver physiology, Jan, Volume: 288, Issue:1
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
AID1848010Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as upregulation of Ucp1 expression in inguinal white adipose tissue at 50 mg/kg2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848003Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in fat/lean index 50 mg/kg, IG measured after 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID678823TP_TRANSPORTER: uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID1848071Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as reduction in bile acid loss in cecum content2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848072Anti-NASH activity in GAN diet-induced C57/BL67 mouse assessed as bile acid level in serum2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1847978Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced Shp mRNA expression in ileum at 10 mg/kg, po incubated for 2 to 48 hrs2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID1848000Anti-NASH activity in GAN-induced C57/BL67 mouse assessed as reduction in body weight at 50 mg/kg, IG measured after 12 weeks2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (25.53)18.7374
1990's9 (19.15)18.2507
2000's9 (19.15)29.6817
2010's11 (23.40)24.3611
2020's6 (12.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.36 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.89%)0.25%
Other52 (98.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]